American Vanguard Misses EPS by $0.60, Cuts 2026 Outlook

American Vanguard reported a quarterly loss of $0.61 per share on Monday, missing the consensus estimate of a $0.01 loss by $0.60, according to Zacks. The shortfall lands at a moment when every dollar of headroom matters: gross leverage sits at 6.5x against a 6.7x covenant ceiling, and the stock now trades near a fifty-two week low of $0.81.

Revenue came in at $108.38 million for the quarter, well below the $130.00 million analysts expected. The basic materials company, which develops crop protection chemicals through its AMVAC subsidiary, also posted a negative return on equity of 9.05% and a negative net margin of 10.70%.

What drove the third-quarter miss?

Sales fell 9% year over year to $108 million, and adjusted EBITDA landed at roughly break-even, down $8.3 million from the prior-year quarter. Gross margin contracted to 24.2% from 28.7%.

The squeeze came from several directions at once. Higher freight and raw-material costs combined with weaker international demand to outweigh two genuine bright spots: improved manufacturing performance and lower operating expenses. Management said it could not raise prices quickly enough to offset rising fuel and raw-material input costs.

How much did guidance come down?

The cuts were substantial. For 2026, American Vanguard now expects:

• Revenue of $500 million to $530 million, down from prior guidance of $530 million to $550 million
• Adjusted EBITDA of $36 million to $40 million, down from $44 million to $48 million

Management pointed again to international weakness and the lag between input-cost inflation and its ability to reprice products.

Is liquidity improving?

The balance sheet tells a mixed story. Cash rose $40 million sequentially to $84 million, helped by customer prepayments that climbed 44% year over year. Net debt fell to approximately $184 million.

But leverage remains the binding constraint. Gross leverage of 6.5x sits just under the 6.7x covenant maximum, leaving limited headroom for error. The company carries a debt-to-equity ratio of 1.46, a current ratio of 2.47 and a quick ratio of 1.40.

What does the fourth quarter look like?

Management guided to a stronger close. It forecast fourth-quarter sales of about $166 million, up 10% year over year, and adjusted EBITDA of $21 million, up roughly 25%.

The outlook rests on four pillars: improved U.S. sales, new products and portfolio additions, better manufacturing absorption, and cost savings. Management offered one clear caution, noting that fourth-quarter business is not yet fully secured.

Where will growth come from?

Two portfolio moves anchor the growth plan. A Syngenta brand acquisition and a Sipcam distribution agreement are projected to add $15 million to $20 million in annualized revenue over the next 12 months.

The company also reiterated a longer-horizon target: exceeding a $600 million annualized sales run rate by the second half of 2028, with double-digit EBITDA margins.

How are insiders and analysts positioned?

Director Keith Rosenbloom sold 556,580 shares on Tuesday, August 18th, at an average price of $2.20, for a total of $1,224,476.00. The sale cut his position by 97.34%; he retained 15,201 shares valued at approximately $33,442.20. The transaction was disclosed in an SEC filing.

One day earlier, on Monday, August 17th, Director Steven D. Macicek moved in the opposite direction. He acquired 19,000 shares at an average cost of $2.09 per share, a total of $39,710.00, increasing his position by 23.54% to 99,711 shares valued at $208,395.99. Insiders own 5.60% of the stock.

The sell side has turned decisively negative. Wall Street Zen downgraded the shares from "hold" to "sell" on Saturday, August 15th, and Weiss Ratings reaffirmed a "sell (e+)" rating on Thursday, August 13th. Based on MarketBeat.com data, the stock carries an average rating of "Sell."

Where does the stock trade now?

Shares opened at $0.82 on Tuesday, against a fifty-two week range of $0.81 to $5.55. The 50-day moving average stands at $1.63 and the 200-day moving average at $2.78. The company has a market cap of $24.13 million, a P/E ratio of -0.43 and a beta of 1.56.

The plain takeaway: a $0.60 EPS miss, a guidance cut of up to $8 million on EBITDA, and 0.2x of covenant headroom leave American Vanguard needing its fourth-quarter forecast — and its Syngenta and Sipcam additions — to deliver on schedule.